|Mr. Timothy William Watts||CEO & Director||N/A||N/A||1958|
|Mr. Hans-Peter Rudolf||Chief Financial Officer||N/A||N/A||N/A|
|Fleur Wood||Director of Investor Relations||N/A||N/A||N/A|
|Ms. Lucy Huntington-Bailey||Gen. Counsel & Company Sec.||N/A||N/A||N/A|
|Ms. Suzanne Wood||Group HR Director||N/A||N/A||N/A|
|Mr. Paul Steckler||Chief Commercial Officer||N/A||N/A||N/A|
|Ms. Carol Akinola||Head of Pharmacovigilance & Medical Information||N/A||N/A||N/A|
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of late-stage pharmaceuticals to treat unmet medical needs. The company's lead product is Ferric Maltol, marketed in the European Union as Feraccru, a non-salt based novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also develops PT30 to treat hypo-allergenic IV iron therapy; and PT40, the first generic version of iron sucrose. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Shield Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.